You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Izba Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Izba patents expire, and what generic alternatives are available?

Izba is a drug marketed by Novartis and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-nine patent family members in twenty-three countries.

The generic ingredient in IZBA is travoprost. There are fifteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the travoprost profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Izba

A generic version of Izba was approved as travoprost by CHARTWELL RX on March 1st, 2013.

  Try a Trial

Paragraph IV (Patent) Challenges for IZBA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
IZBA Ophthalmic Solution travoprost 0.003% 204822 1 2015-12-30

US Patents and Regulatory Information for Izba

Izba is protected by four US patents.

Patents protecting Izba

Pharmaceutical compositions having desirable bioavailability
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical compositions having desirable bioavailability
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical compositions having desirable bioavailability
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical compositions having desirable bioavailability
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis IZBA travoprost SOLUTION/DROPS;OPHTHALMIC 204822-001 May 15, 2014 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Novartis IZBA travoprost SOLUTION/DROPS;OPHTHALMIC 204822-001 May 15, 2014 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Novartis IZBA travoprost SOLUTION/DROPS;OPHTHALMIC 204822-001 May 15, 2014 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Novartis IZBA travoprost SOLUTION/DROPS;OPHTHALMIC 204822-001 May 15, 2014 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for Izba

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Novartis Europharm Limited Izba travoprost EMEA/H/C/002738
Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.
Authorised no no no 2014-02-20
Novartis Europharm Limited Travatan travoprost EMEA/H/C/000390
Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).
Authorised no no no 2001-11-27
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for Izba

See the table below for patents covering Izba around the world.

Country Patent Number Title Estimated Expiration
Japan 2011514384 ⤷  Try a Trial
Spain 2637028 ⤷  Try a Trial
Hong Kong 1220378 具有所需生物利用度的藥物組合物 (PHARMACEUTICAL COMPOSITIONS HAVING DESIRABLE BIOAVAILABILITY) ⤷  Try a Trial
Canada 2716994 COMPOSITIONS PHARMACEUTIQUES AYANT LA BIODISPONIBILITE SOUHAITABLE (PHARMACEUTICAL COMPOSITIONS HAVING DESIRABLE BIOAVAILABILITY) ⤷  Try a Trial
European Patent Office 2705836 Compositions pharmaceutiques à biodisponibilité souhaitable (Pharmaceutical compositions having desirable bioavailability) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for Izba

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1920764 1290027-0 Sweden ⤷  Try a Trial PRODUCT NAME: TRAVOPROST
1514548 CA 2014 00038 Denmark ⤷  Try a Trial PRODUCT NAME: TRAVOPROST; REG. NO/DATE: EU/1/01/199/001-002 20011127
1514548 PA2014029 Lithuania ⤷  Try a Trial PRODUCT NAME: TRAVOPROSTUM; REGISTRATION NO/DATE: EU/1/01/199/001 - EU/1/01/199/002 20011129
1920764 C01920764/01 Switzerland ⤷  Try a Trial PRODUCT NAME: TRAVOPROST; REGISTRATION NUMBER/DATE: SWISSMEDIC 55910 22.05.2002
1920764 PA2012017,C1920764 Lithuania ⤷  Try a Trial PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.